Safety, Immunology, and Interactions of BNT162b2 and mRNA-1273 COVID-19 Vaccines Given as Boosters of the Fourth Dose Following Two Doses of ChAdOx1 nCoV-19 or BNT162b2 and the Third Dose of BNT162b2 (COV-BOOST): A multicenter, blinded, phase 2, randomized trial

Safety, Immunology, and Interactions of BNT162b2 and mRNA-1273 COVID-19 Vaccines Given as Boosters of the Fourth Dose Following Two Doses of ChAdOx1 nCoV-19 or BNT162b2 and the Third Dose of BNT162b2 (COV-BOOST): A multicenter, blinded, phase 2, randomized trial

SARS-CoV-2 Anticancer protein IgG concentration, ELU/ml Day 28 after the third dose 2325 (20 030-27162); 66 25317 (20996-30528); 66 20 502 (16473-25 517); 35 21 980 (1676-29 324); 33 26982 (22056–33008); 31 29161 (23093–36 823); 33 Day 0 of the fourth dose 3049 (2550–3646); 66 3469 (2730-4407); 66 2532 (1974-3247); 35 2571 (1874–3527); 34 3761 (2959-4780); 31 4769 (3421–6648); 32 Fourteenth day after the fourth dose 37460 (31996-43 857); 65 54936 (46826 – 64452); 67 33316 (26942-41 198); 35 52 080 (41163-65 894); 34 42949 (34148-54 019); 30 58 043 (46693-72 150); 33 Fold change (day 14 after the fourth dose against day 28 after the third dose) 1 59 (1 41-1 78); 65 2 19 (1 90-2 52); 66 1 62 (1 35-1 95); 35 2 41 (1 90-3 05); 33 1 54 (1 35-1 76); 30 1 99 (1 71-2 31); 33 Fold change (day 14 after the fourth dose against day 0 of the fourth dose) 12 19 (10 37-14 32); 65 15 90 (12 92 – 19 58); 66 13 16 (10, 24-16, 91); 35 20 26 (15 09 – 27.21); 34 11 14 (9 21-13 47); 30 12 30 (9 39-16 11); 32 Cellular response (wild-type), spot cells make up for every 106 PBMCs

*

Due to logistical reasons, only 50% of the study sites collected immune cellular samples (near the outside laboratory) in the main COV-BOOST study; Cellular immunostaining samples were collected after the fourth dose in an immunology group.